(NASDAQ: APRE) Aprea Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.89%.
Aprea Therapeutics's earnings in 2025 is -$14,081,279.On average, 2 Wall Street analysts forecast APRE's earnings for 2025 to be -$5,144,177, with the lowest APRE earnings forecast at -$5,254,804, and the highest APRE earnings forecast at -$5,033,549. On average, 2 Wall Street analysts forecast APRE's earnings for 2026 to be -$4,397,442, with the lowest APRE earnings forecast at -$4,756,981, and the highest APRE earnings forecast at -$4,037,902.
In 2027, APRE is forecast to generate $829,706 in earnings, with the lowest earnings forecast at $829,706 and the highest earnings forecast at $829,706.